← Eichor
Condition: Systemic Lupus Erythematosus Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Systemic Lupus Erythematosus

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
Phase N/A · 1 location(s) · Children's National Research Institute · NCT04833465LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus
NA · 14 location(s) · Heinrich-Heine University, Duesseldorf · NCT05714930Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Phase 1 · 18 location(s) · Regeneron Pharmaceuticals · NCT06975787Systemic Lupus Erythematosus in Gullah Health
Phase N/A · 1 location(s) · Medical University of South Carolina · NCT00756769Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Sy
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT05927688US Zamto-cel Autoimmune Diseases
Phase 1 · 1 location(s) · Miltenyi Biomedicine GmbH · NCT06708845Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
Phase 1 · 3 location(s) · HC Biopharma Inc. · NCT06657703A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
Phase 2 · 2 location(s) · Guangdong Hengrui Pharmaceutical Co., Ltd · NCT07299422A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542Duke Lupus Registry
Phase N/A · 1 location(s) · Duke University · NCT00512694Dose Response of Exercise for Arthritis Management
NA · 1 location(s) · University of South Carolina · NCT06880653Deciphering the Genetic Architecture of Autoimmune Diseases
Phase N/A · 2 location(s) · National Human Genome Research Institute (NHGRI) · NCT06948110Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Juventas Cell Therapy Ltd. · NCT06316791Lupus Landmark Study: A Prospective Registry and Biorepository
Phase N/A · 25 location(s) · Lupus Research Alliance · NCT05934149A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Phase 1 · 2 location(s) · Beijing GoBroad Hospital · NCT06980597Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel
EARLY_Phase 1 · 1 location(s) · Changhai Hospital · NCT07246096RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic
Phase 1/Phase 2 · 23 location(s) · Cabaletta Bio · NCT06121297A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
Phase 2 · 82 location(s) · Zenas BioPharma (USA), LLC · NCT06559163A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Pati
Phase 2 · 101 location(s) · Novartis Pharmaceuticals · NCT06581198Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
Phase N/A · 1 location(s) · University Hospital, Toulouse · NCT05251415Safety of Administering Isoniazid to SLE Patients to Prevent TB
Phase 2/Phase 3 · 1 location(s) · Universitas Padjadjaran · NCT06618573A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I
Phase 2 · 96 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07015983Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus
Phase N/A · 1 location(s) · Cliniques universitaires Saint-Luc- Université Catholique de · NCT05443516PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
Phase 4 · 15 location(s) · Aurinia Pharmaceuticals Inc. · NCT07611214A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants Wit
Phase 1 · 37 location(s) · AstraZeneca · NCT06916806Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis
Phase 4 · 1 location(s) · Institutul Clinic Fundeni · NCT05207358Biomarker Development for Autoimmune Disorders Involving the Kidneys
Phase N/A · 1 location(s) · Oslo University Hospital · NCT07666711A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Phase 1 · 19 location(s) · GlaxoSmithKline · NCT07371468Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06428188A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
Phase 3 · 1 location(s) · Beijing Mabworks Biotech Co., Ltd. · NCT07405970
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.